Microbot Medical's LIBERTY System Gains Traction at ISET Conference
Event summary
- Microbot Medical's LIBERTY Endovascular Robotic System featured at the International Symposium on Endovascular Therapy (ISET) conference, February 9-12, 2026.
- LIBERTY highlighted in a Town Hall session discussing the future of single-use handheld vascular robots.
- System used across multiple hospitals for a wide range of procedure types, including complex cases.
- Limited market release (LMR) commenced in late 2025, with full market release planned for April 2026 at the Society of Interventional Radiology (SIR) conference.
The big picture
Microbot Medical's LIBERTY System is positioning itself as a key player in the evolving landscape of endovascular robotics. The system's FDA clearance and growing clinical relevance across multiple specialties underscore its potential to reshape peripheral endovascular procedures. The upcoming full market release at the SIR conference in April 2026 will be a critical milestone in assessing its long-term market impact.
What we're watching
- Market Adoption
- The pace at which LIBERTY gains broader adoption among interventional radiologists, vascular surgeons, and other clinical decision makers.
- Regulatory Approval
- Whether the FDA clearance and positive feedback from key opinion leaders will translate into sustained commercial success.
- Competitive Positioning
- How LIBERTY's unique features, such as seamless workflow integration and radiation reduction, will differentiate it in the peripheral endovascular intervention space.
Related topics